New Haven, Conn., July 17, 2026
Veradermics announced the presentation of new subgroup analysis data from its Phase 2/3 Study ‘302’ evaluating VDPHL01, an investigational extended-release oral minoxidil formulation, in men with mild-to-moderate pattern hair loss. The results were presented during a poster session on July 16 and an oral presentation on July 17 at the 2026 American Academy of Dermatology (AAD) Innovation Academy in New York City.
Subgroup Analysis Evaluates Treatment Response by Age
Study ‘302’ is a randomized, double-blind, placebo-controlled Phase 2/3 trial enrolling more than 500 male patients with mild-to-moderate pattern hair loss. The newly presented subgroup analysis assessed the efficacy and safety of VDPHL01 in two age groups: men younger than 40 years and those 40 years and older, providing additional insight into treatment performance across different patient populations.
Phase 3 Development Program Continues to Advance
The presentation builds on Veradermics’ ongoing late-stage clinical development program for VDPHL01 in both male and female pattern hair loss. Earlier this year, the company reported topline results from Study ‘302’ and completed enrollment in its second Phase 3 male trial, Study ‘304’, with topline results expected during the second half of 2026. Veradermics also recently announced positive topline results from Study ‘207’ in female pattern hair loss, while registration-directed Study ‘306’ is expected to report topline data during the first half of 2027.
Advertisement
VDPHL01 Targets Significant Unmet Need in Hair Loss Treatment
VDPHL01 is a proprietary extended-release oral, non-hormonal minoxidil tablet designed to provide sustained drug absorption while reducing peak systemic exposure associated with immediate-release formulations. The investigational therapy is intended to improve efficacy while minimizing cardiovascular risk. If approved, VDPHL01 would become the first FDA-approved oral non-hormonal treatment for both male and female pattern hair loss, addressing a condition affecting an estimated 80 million people in the United States and a global market projected to reach approximately $30 billion by 2028.
Source: Veradermics press release
